Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MP0714
- Development stage
- Preclinical
- Lead developer
- Molecular Partners
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MP0714 is a preclinical-stage targeted alpha radiopharmaceutical being developed by Molecular Partners. It consists of a designed ankyrin repeat protein (DARPin) vector targeting delta-like ligand 3 (DLL3) conjugated to either the alpha-emitting radioisotope actinium-225 (225Ac) for therapy or the beta-emitting radioisotope lutetium-177 (177Lu) for imaging, forming a theranostic pair. MP0714 is designed to treat small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs) by selectively delivering cytotoxic radiation to DLL3-expressing tumor cells. An early-access clinical program for compassionate care has been initiated in South Africa by the Nuclear Medicine Research Institute (NuMeRI) to image and treat patients using this theranostic pair.
- Other names
- 177Lu/225Ac DLL3 Radio-DARPin225Ac-DLL3 Radio-DARPinDLL3-targeting Radio-DARPin (177Lu/225Ac)
02
Targets
DNADLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on MP0714.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MP0714.